Pharmacologic Management of the Cardio-renal Syndrome.
- Author:
Chang Seong KIM
1
Author Information
- Publication Type:Review
- Keywords: Cardio-renal syndrome; Management; Drug
- MeSH: Adenosine A1 Receptor Antagonists; Aspirin; Cardio-Renal Syndrome; Consensus; Diuretics; Dopamine; Erythropoietin; Heart; Heart Failure; Humans; Iron; Kidney; Phosphodiesterase Inhibitors; Renal Insufficiency; Vasopressins
- From:Electrolytes & Blood Pressure 2013;11(1):17-23
- CountryRepublic of Korea
- Language:English
- Abstract: Cardio-renal syndromes are disorders of the heart and kidney wherein acute or long-term dysfunction in one organ may induce acute or long-term dysfunction of the other. Because of this complex organ interaction, management of cardiorenal syndrome must be tailored to the underlying pathophysiology. Clinical guidelines exist for the treatment of heart failure or renal failure as separate conditions. Thus far, however, there has been no consensus about managing patients with cardio-renal and reno-cardiac syndromes. Pharmacologic treatment remains a controversial subject. Standard cardiac drugs such as diuretics and inotropes may have limited effect because resistance often develops after long-term use. Recent studies of patients with acute cardio-renal syndromes have focused on newer therapies, including phosphodiesterase inhibitors, vasopressin antagonists, adenosine A1 receptor antagonists, and renal protective dopamine. Initial clinical trials of these agents have shown encouraging results in some patients with heart failure, but have failed to demonstrate a clear superiority over more conventional treatments. Similarly, the benefits of diuretics, aspirin, erythropoietin agents, and iron supplements for management of chronic cardiorenal syndromes are unknown.
